Short Term Corticosteroids in SARS-CoV2 Patients
The Effect of the Short-term Use of Systemic Corticosteroids in COVID-19 Patients in Regard to Hospital Length of Stay, Morbidly and/or Mortality.
1 other identifier
observational
50
1 country
1
Brief Summary
The investigators reviewed the charts of SARS-CoV-2 patients with pneumonia and moderate to severely elevated CRP and worsening hypoxemia who were treated with early, short-term dexamethasone.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Apr 2020
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 31, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
May 31, 2020
CompletedFirst Submitted
Initial submission to the registry
June 19, 2020
CompletedFirst Posted
Study publicly available on registry
June 24, 2020
CompletedJune 24, 2020
May 1, 2020
2 months
June 19, 2020
June 22, 2020
Conditions
Outcome Measures
Primary Outcomes (1)
Effect on transfers to ICU and escalation of care needing mechanical ventilation
2 months
Secondary Outcomes (2)
Effect on length of stay
2 months
Change in CRP levels
2 months
Study Arms (1)
SARS-CoV2 patients that received dexamethasone
Interventions
4mg dexamethasone was given to some patients three times daily for 2 days, 2 times daily for 2 days, once daily for 2 days.
Eligibility Criteria
All patients aged 18 years and older with positive SARS-CoV2 test with CRP greater than 50 mg/L and having greater than 2L Oxygen requirement
You may qualify if:
- Moderate disease with at least a 30% increase in CRP within 36 hours of admission, and with increasing oxygen requirements.
- All patients with severe disease with evidence of escalating oxygen requirements
- The presence of secondary bacterial infections as a probable cause of increasing CRP levels was excluded in all selected patients.
- Pulmonary embolism and /or cardiac dysfunction were excluded as probable causes of worsening hypoxia in all selected patients.
You may not qualify if:
- All patients on other treatment modalities- Remdesivir and/or Convalescent plasma who showed evidence of clinical improvement as per decrease in CRP levels and/or oxygen requirements were excluded.
- Patient with associated COPD exacerbation who would benefit from the use of steroids.
- Patients with Diabetic ketoacidosis, hyperglycemic hyperosmolar state, active concurrent bacterial infections.
- Patients with history of steroid-induced mania and/or psychosis.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
The Miriam Hospital
Providence, Rhode Island, 02906, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Kwame Dapaah-Afriyie, MD
The Miriam Hospital
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 19, 2020
First Posted
June 24, 2020
Study Start
April 1, 2020
Primary Completion
May 31, 2020
Study Completion
May 31, 2020
Last Updated
June 24, 2020
Record last verified: 2020-05